Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin.

Wang F, Yang Y.

DOI: 10.1007/s10549-014-3068-6
Published: 2014-08-02
Container: Breast Cancer Res Treat
Publisher: Not recorded
Open access: no

Credibility signals

serious concern Score 8/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
serious concernRetraction Watch retraction: 1 retraction notice matched this DOI. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10549-014-3068-6,
  title = {Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin.},
  author = {Wang F and  Yang Y.},
  year = {2014},
  journal = {Breast Cancer Res Treat},
  doi = {10.1007/s10549-014-3068-6},
  url = {https://doi.org/10.1007/s10549-014-3068-6}
}

RIS

TY  - JOUR
TI  - Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin.
AU  - Wang F
AU  -  Yang Y.
PY  - 2014
JO  - Breast Cancer Res Treat
DO  - 10.1007/s10549-014-3068-6
UR  - https://doi.org/10.1007/s10549-014-3068-6
ER  -

APA

F, W., & Y., Y. (2014). Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin.. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-014-3068-6

Source records

europe-pmc · retrieved 2026-11-10T19:54:43.636Z